A federal consultative group voted Thursday to soften rules on seven peptides, including BPC-157 and TB-500. The vote was narrow. It is non-mandatory. The FDA has given no signal on whether it will move in step with the panel. The move came after weeks of stakeholder sessions. Wellness backers pressed firmly for wider access. RFK Jr. was among them. Critics say these compounds have weak safety evidence or help for most uses. The call could redefine how the agency handles a part of the wellness market that is moving at speed. Watchers are waiting to see if the agency adopts the plan. A spokesperson offered no clear schedule for a response. Backers argue the change would open up access to substances some say help. Safety voices warn that looser rules could weaken safeguards across a fast-scaling market. The vote only sets up a possible shift, and the final call rests with the agency.
Sources & References
-
FDA panel recommends loosening restrictions on controversial peptide - The Washington Post
FDA panel recommends loosening restrictions on controversial peptide The Washington Post
-
An FDA Committee Just Voted in Favor of Peptides-Despite the Agency's Opposition - Time Magazine
An FDA Committee Just Voted in Favor of Peptides-Despite the Agency's Opposition Time Magazine
-
FDA Advisory Panel Weighs Access to 7 Popular Peptides This Week - The American Journal of Managed Care
FDA Advisory Panel Weighs Access to 7 Popular Peptides This Week The American Journal of Managed Care
-
FDA panel narrowly backs unapproved peptide drugs favored by RFK Jr. and wellness influencers - AP News
FDA panel narrowly backs unapproved peptide drugs favored by RFK Jr. and wellness influencers AP News
-
Most FDA advisers say peptides like BPC-157 and TB-500 should be made available in the U.S. Here's what happens next. - MarketWatch
Most FDA advisers say peptides like BPC-157 and TB-500 should be made available in the U.S. Here's what happens next. MarketWatch